In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Alimera (ALIM), with a price target of $16.00. The company’s shares closed last Wednesday at $10.97, close to its 52-week high of $12.25.
According to TipRanks.com, Chen is a top 100 analyst with an average return of 65.9% and a 53.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics.
Currently, the analyst consensus on Alimera is a Moderate Buy with an average price target of $15.50.
See today’s analyst top recommended stocks >>
Alimera’s market cap is currently $55M and has a P/E ratio of -9.90. The company has a Price to Book ratio of -1.48.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.
